News
Press Releases
2015/05/22
Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx
SHANGHAI, May 22, 2015 /PRNewswire/ -- A consortium ("the Consortium") consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited's healthcare fund ("CEL Healthcare Fund"), and WuXi PharmaTech announced today that the Consortium has signed a merger agreement pursuant to which the Consortium will acquire Ambrx Inc. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.
Read more2015/05/21
WuXi Launches e-Commerce Platform for Chemistry Products
SHANGHAI, May 21, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced the launch of LabNetwork (www.labnetwork.com). LabNetwork is a global e-Commerce platform for connecting buyers and sellers of research chemicals and reagents. Backed by WuXi's world-class expertise in chemistry R&D, sourcing, and quality control, LabNetwork will bring trusted, novel, and high-quality compounds from WuXi's global network of qualified providers to the chemistry and research communities worldwide.
Read more2015/04/23
WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, today announced that it will release financial results for the first quarter of 2015 after the New York Stock Exchange closes on Wednesday, May 13, 2015 (which will be Thursday morning, May 14, 2015 Shanghai time).
Read more2015/04/08
Nobel Prize Laureate Professor Barry Sharpless Visits WuXi AppTec Headquarters in Shanghai
SHANGHAI, April 8, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, announced today that Professor Barry Sharpless visited WuXi AppTec's Shanghai headquarters on April 8 and gave an inspiring scientific lecture. Professor Sharpless holds the W. M. Keck professorship in chemistry at The Scripps Research Institute. His visit was part of the 2015 Distinguished Lecture Series, an annual program at WuXi since 2007 that aims to train and inspire WuXi's scientists to pursue scientific excellence.
Read more2015/04/02
WuXiPharmaTechLists Shares of Small-Molecule Manufacturing Subsidiary STA on New Third Board in China
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, announced today that its wholly owned subsidiary SynTheAll Pharmaceutical Co. Ltd. ("STA") has received approval from the National Equities Exchange and Quotations ("NEEQ") in China to list its shares on the New Third Board, the over-the-counter (OTC) stock exchange in China.
Read more